Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 9/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MBTD1 | Q05BQ5 | 5/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.32 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20438258 | 1.00 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| Hydrochloric Acid SCHEMBL22190827 | 0.97 | L3MBTL3 (0.37) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| Hydrochloric Acid SCHEMBL20421821 | 0.97 | L3MBTL3 (0.37) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL1543190 | 0.94 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL11942150 | 0.94 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL3195988 | 0.94 | L3MBTL3 (0.43) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL372231 | 0.92 | CYP2D6 (0.42) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| SCHEMBL372230 | 0.92 | CYP2D6 (0.42) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| Hydrochloric Acid SCHEMBL22190785 | 0.92 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 | |
| Hydrochloric Acid SCHEMBL15190812 | 0.92 | L3MBTL3 (0.41) | L3MBTL3L3MBTL1CYP2D6CYP2C19MBTD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | L3MBTL3 4866/4885L3MBTL1 4825/4885CYP2D6 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.